[Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia].
Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.
Okamoto
Shinichiro
S
Division of Hematology, Department of Medicine, Keio University School of Medicine.
D000367:Age Factors; D000741:Anemia, Aplastic / Q000628:therapy*; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006648:Histocompatibility; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D006680:HLA Antigens